HLT:PA:PA-Lyxor Index Fund - Lyxor STOXX Europe 600 Healthcare UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 138.824

Change

0.00 (0.00)%

Market Cap

USD 0.77B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

+0.43 (+0.97%)

USD 56.03B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+13.50 (+2.78%)

USD 13.60B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+9.94 (+2.85%)

USD 11.29B
WRD:PA HSBC MSCI World UCITS ETF

+0.81 (+2.51%)

USD 11.04B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

+4.60 (+1.84%)

USD 10.45B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

+16.10 (+3.86%)

USD 8.68B
WLD:PA Lyxor UCITS MSCI World D-EUR

+7.96 (+2.50%)

USD 7.49B
HHH:PA HSBC S&P 500 UCITS ETF

+1.39 (+2.84%)

USD 7.22B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

+0.27 (+4.42%)

USD 6.16B
SPY4:PA SSgA SPDR S&P 400 US Mid Cap

+2.33 (+3.04%)

USD 5.38B

ETFs Containing HLT:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.85% 46% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.85% 45% F 45% F
Trailing 12 Months  
Capital Gain -5.74% 10% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.74% 10% F 34% F
Trailing 5 Years  
Capital Gain 26.34% 30% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.34% 29% F 44% F
Average Annual (5 Year Horizon)  
Capital Gain 8.69% 55% F 63% D
Dividend Return 8.69% 51% F 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.34% 73% C 86% B+
Risk Adjusted Return 104.14% 88% B+ 92% A
Market Capitalization 0.77B 74% C 75% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike